cjc-1295 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
=== Reporting dates === Several formats for citing radiocarbon results have been used since the first samples were dated. As of 2019, the standard format required by the journal Radiocarbon is as follows. Uncalibrated dates should be reported as "laboratory:
=== Variations === Novolog Mix 70/30 is a product which contains 30% insulin aspart and 70% insulin aspart protamine. The insulin aspart protamine portion is a crystalline form of insulin aspart, which delays the action of the insulin, giving it a prolonged absorption profile after injection. The combination of the fast-acting form and the long-acting form allows the patient to receive fewer injections over the course of the day. Novolog Mix is marketed to be used with the Novo Nordisk Flexpen. The onset of action is less than 30 minutes, the peak action is reached in 1–4 hours, and the duration is less than 24 hours. NovoLog Mix is marketed in some countries as NovoMix 30. NovoRapid is produced in Saccharomyces cerevisiae by recombinant DNA technology. A faster acting version of aspart insulin, known as fast-aspart (Fiasp) insulin, is associated with more efficient control of post-prandial rise in blood glucose, without increasing the risks of hypoglycemia and glycemic variability.
==== Issue of citizenship ==== The report further stated that Russian citizenship, given to the vast part of Abkhaz and Ossetians can not be considered "legally binding under international law" and "the purportedly naturalised persons from South Ossetia and Abkhazia are not Russian nationals in terms of international law." The commission concluded that Abkhaz and South Ossetians legally were citizens of Georgia since 1993, and had not lost their Georgian citizenship at the time of the conflict. The commission also concluded: "The large-scale naturalisations of residents of South Ossetia and Abkhazia with no other factual connection to Russia must be equated to so-called collective (ex lege) naturalisations of foreign residents", which was prohibited. The commission concluded that the creation of Russian citizens in Georgia massively "may be a basis (or rather a pretext) for military intervention", and would amount as a violation of Georgia's sovereignty. The commission concluded that some parts of the Russian Law on Citizenship violated a territorial sovereignty of Georgia. The commission made conclusions that Russian "passportisation" was a meddling in Georgian affairs and demonstrated that Russia was the bad neighbour. The commission stated that humanitarian obstacles caused by Russia to the residents of Abkhazia and South Ossetia "do not justify the large-scale naturalisation of Georgian citizens." The commission stated that "Russia is not allowed under international law to issue passports directly in South Ossetia and Abkhazia, and to pay pensions there".
Cave paintings from more than 3,500 years ago document burns and their management. The earliest Egyptian records on treating burns describes dressings prepared with milk from mothers of baby boys, and the 1500 BCE Edwin Smith Papyrus describes treatments using honey and the salve of resin. Many other treatments have been used over the ages, including the use of tea leaves by the Chinese documented to 600 BCE, pig fat and vinegar by Hippocrates documented to 400 BCE, and wine and myrrh by Celsus documented to the 1st century CE. French barber-surgeon Ambroise Paré was the first to describe different degrees of burns in the 1500s. Guillaume Dupuytren expanded these degrees into six different severities in 1832. The first hospital to treat burns opened in 1843 in London, England, and the development of modern burn care began in the late 1800s and early 1900s. During World War I, Henry D. Dakin and Alexis Carrel developed standards for the cleaning and disinfecting of burns and wounds using sodium hypochlorite solutions, which significantly reduced mortality. In the 1940s, the importance of early excision and skin grafting was acknowledged, and around the same time, fluid resuscitation and formulas to guide it were developed. In the 1970s, researchers demonstrated the significance of the hypermetabolic state that follows large burns. The "Evans formula", described in 1952, was the first burn resuscitation formula based on body weight and surface area (BSA) damaged.
Sources: en.wikipedia.org
The Wound Man is a surgical diagram which first appeared in European medical manuscripts of the fourteenth and fifteenth centuries. The illustration acted as an annotated table of contents to guide the reader through various injuries and diseases whose related cures could be found on the text's nearby pages. The image first appeared in a printed book in 1491 when it was included in the Venetian Fasciculus medicinae, likely Europe's first printed medical miscellany. Thereafter it circulated widely in printed books until well into the seventeenth century. The Wound Man has since become a recognisable figure in popular culture.
Bags of potatoes are sometimes stacked in customer spaces due to an occasional lack of storage space, or, in some franchises, for aesthetic reasons. Restaurants are decorated with white and red checkered tile throughout and generally use wooden tables along with counter-high level seating.
Leroy Hood is a member of the National Academy of Sciences (NAS, 1982), the National Academy of Engineering (2007), the National Academy of Medicine (formerly the Institute of Medicine, 2003), and the National Academy of Inventors (2012). He is one of only 15 scientists ever elected to all three national academies. He is also a member of the American Academy of Arts and Sciences (1982), a member of the American Philosophical Society (2000), a fellow of the American Society for Microbiology, and a charter fellow of the National Academy of Inventors (2012).
== Synthesis == After the biotech company Genentech discovered and patented the gene for BST in the 1970s, it became possible to synthesize the hormone using recombinant DNA technology to create recombinant bovine somatotropin (rBST), recombinant bovine growth hormone (rBGH), or artificial growth hormone.
=== Hantzsch pyridine synthesis === The Hantzsch dihydropyridine synthesis employs two molecules of a 1,3-dicarbonyl compound (for example ethyl acetoacetate), together with an aldehyde and one molecule of ammonia. These components condense to form a symmetrical 1,4-dihydropyridine derivative, which undergoes aromatization by oxidation to yield a pyridine. A wide range of oxidizing agents is suitable for this final oxidation step; in some cases, exposure of the intermediate to air is sufficient. Alternatively, activated carbon with adsorbed oxygen or catalysts such as palladium or the enzyme laccase can be used to promote air oxidation. A one-pot reaction for pyridine synthesis based on the Hantzsch reaction starts from acetoacetic ester and an aldehyde. The reaction is performed under microwaves and in the presence of bentonite as an acidic catalyst. Ammonium nitrate serves both as an ammonia equivalent and as an oxidizing agent for the oxidation of the dihydropyridine intermediate. This method has been used as a basis for the combinatorial chemistry of pyridines to generate molecular libraries.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.